Septerna bags $288M upsized IPO for GPCR drugs
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday. Investors seemed enthused by the prospects of the GPCR biotech. They...
View ArticleClik here to view.
Elucida Oncology shutters due to 'lack of funding'
Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has learned. The New Jersey startup was trying to take a different approach in the...
View ArticleEnGene’s $60M PIPE; AbbVie to develop neuropsychiatric drugs with Gedeon Richter
Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences: EnGene snags $60M: The Boston and Montreal gene therapy biotech raised the private placement from new and current...
View ArticleBristol Myers, Ideaya report new data for solid tumors with MTAP deletion
Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting solid tumors with a certain mutation known as MTAP deletion. There are no...
View ArticleClik here to view.
Lyell Immunopharma to acquire ImmPACT Bio, cut top programs
Lyell Immunopharma is discontinuing several programs and acquiring CAR-T biotech ImmPACT Bio and its suite of clinical-stage candidates for $30 million in upfront cash and 37.5 million shares of...
View ArticleClik here to view.
Tyra Biosciences gives a first look at its challenge to J&J’s targeted...
Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first presentation of human data since its inception in...
View ArticleWhy are Lilly and Roche trying to block Novo's deal for Catalent?
This week, Roche joined Eli Lilly in coming out against a deal that would add significant new manufacturing capacity to Novo Nordisk, to help it meet some of the huge demand for its GLP-1 drugs Wegovy...
View ArticleClik here to view.
New radiopharma spinout Rhine Pharma banks on one trial for success, Telix...
The future of Telix Pharmaceuticals’ new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO Christian Behrenbruch told Endpoints News in an interview. Christian Behrenbruch...
View ArticleClik here to view.
FDA approves new type of oral antibiotic for UTIs
The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who have limited or no alternative oral options. Orlynvah, also known as oral...
View ArticleHouse Republicans push for more transparency on government-funded trial data
A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data funded by taxpayers after a New York Times story ran this week that said an...
View ArticleHungary's Olivér Várhelyi readies to be EU health commissioner, pledging...
On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new commissioner-designate for health and animal welfare with a full plate of pharma-related...
View ArticleRevolution Medicines breaks ground in challenging pancreatic cancer with two...
In an interview Friday, Revolution Medicines CEO Mark Goldsmith, who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer — or get close. “That’s our aim,...
View ArticleLatest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleNovartis pays Monte Rosa $150M for Phase 1 drug in latest endorsement of...
Novartis is getting a hold of one of Monte Rosa Therapeutics’ clinical-stage molecular glues, and it's putting more than $2.2 billion on the table. That includes $150 million upfront for MRT-6160,...
View ArticleFormer Seagen CEO David Epstein to lead new biotech with VEGF bifunctional...
David Epstein, who was the CEO of Seagen when it was acquired by Pfizer for $43 billion last year, is joining a new biotech that’s looking into one of the buzziest approaches ...
View ArticleSynaffix launches startup with pipeline of ADC drugs and $92M
The Dutch biotech Synaffix has long been one of the top partners for biopharma companies working in antibody-drug conjugates. Now the company is spinning out a pipeline of drugs into a new company....
View ArticleHOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning...
HOPO Therapeutics scored a government contract for up to $226 million to develop an oral countermeasure against radiological threats and heavy metal poisoning. The funding from the Biomedical Advanced...
View ArticleAbbVie makes $1.4B acquisition of Alzheimer's biotech
AbbVie said Monday it will pay $1.4 billion in cash to buy a Phase 1 Alzheimer's and neuroscience biotech, extending the company’s reach into CNS R&D and ...
View ArticleBiogen's full Ph2 data for IgA nephropathy drug; Sanofi invests in obesity...
Plus, news about Novartis, CombiGene, ProQR and Aardvark Therapeutics: Biogen presents full Phase 2 data for felzartamab: The drug, which was acquired in Biogen’s $1.15 billion buyout of HI-Bio earlier...
View Article